Furthermore, we provide evidence that when RCC cells are deprived of the glycolysis substrate, they become more sensitive to PPARα antagonists, suggesting that RCC cells alter their energy metabolism pathways under these conditions, and pointing to the feasibility of combination of PPARα antagonists and glycolysis inhibitor therapy for this disease. The gene discussed is PPARA; the disease is renal cell carcinoma.